GlassScriptPhysician profile
Charles L Papp
NPI 1316948664
$9,445.91
in general payments reported to CMS, 2019-2025
47 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what 80% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $672 · 2021: $1,186 · 2022: $1,652 · 2023: $1,594 · 2024: $1,881 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,120 · Education: $42.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,119.55 |
| Education | $42.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,761.96 | 2019-2025 | |
| Janssen Biotech, INC. | $1,611.81 | 2019-2025 | Tremfya, Stelara, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,278.75 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $657.97 | 2019-2025 | Entyvio, Gattex |
| Ferring Pharmaceuticals INC. | $450.81 | 2019-2025 | Rebyota |
| Celgene Corporation | $368.39 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $313.03 | 2023-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $300.00 | 2022-2024 | |
| Qol Medical, LLC | $286.35 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $278.35 | 2022-2025 | |
| Vioptix INC | $248.02 | 2021 | |
| Pfizer INC. | $179.38 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $169.79 | 2022-2025 | Dupixent |
| Amgen INC. | $158.66 | 2020-2023 | Avsola, Amjevita |
| Palette Life Sciences, INC. | $125.38 | 2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Papp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.